Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion type Assertion NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_head.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion description "[Our results suggest that patients with HER2(+) breast cancer may benefit from anti-TBK1/IKK? plus anti-HER2 combination therapies and establish conditions that can be used to screen for additional TIC-specific inhibitors of HER2(+) breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_provenance.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion evidence source_evidence_literature NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_provenance.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion SIO_000772 24487029 NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_provenance.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion wasDerivedFrom befree-20150227 NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_provenance.
- NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_assertion wasGeneratedBy ECO_0000203 NP828575.RALwKAJe3BJaVhIuYs22kvrw2wQ7XPjzHjVezyM0rdD38130_provenance.